Overview
Status
Active
Registry date
2023-08-28
Share capital
5,000.00 PLN
Registered address
Wynalazek 4, 02-677 Warszawa, Poland
Financials
Revenue history (in k)
Filing timeliness
1 of 3 financial statements was filed late (for 2024, 14 days late).
- 202506/07/2026
- 202429/07/2025
- 202303/07/2024
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 1.02mMedianUSD 55.24kAverageUSD 2.71m
Net profit
This companyUSD 120.56kMedianUSD -1.27kAverageUSD -91.85k
Operating costs
This companyUSD 881.86kMedianUSD 65.85kAverageUSD 2.66m
Assets
This companyUSD 343.77kMedianUSD 133.19kAverageUSD 3.03m
Industry
Authorized Representatives
Karolina Anna Kursa – Management Board Member
Piotr Furman – President of the Management Board
Kamila Justyna Królik – Management Board Member
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Piotr Furmanage 39 | 34 | $459.21 | 34% |
Kamila Justyna Królikage 34 | 33 | $445.71 | 33% |
Karolina Anna Kursaage 50 | 33 | $445.71 | 33% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2023-12-08.
05 1050 1012 1000 0090 8275 4012
19 1050 1012 1000 0090 3298 7910
41 1050 1012 1000 0090 3298 7902
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| Orphinic ScientificS.A. | $518,429.97 | orphinic.com | ||
| Proper Medical Writingsp. z o.o. | $464,661.64 | propermedicalwriting.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Explorna Therapeuticssp. z o.o. | $304,662.00 | explorna.com | ||
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl |
FAQ
The main business activity of ETG Neuroscience focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on August 28, 2023.
The headquarters is located at: Wynalazek 4, 02-677 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
The company reported a revenue of $1,098,428 in 2024, which is an increase of 2180.4% compared to 2023.
Yes, in 2024 the company was profitable, achieving a net profit of $135,479, meaning the company increased its profit by 642.9%.
The largest operating cost category falls under external services. This category amounted to $609,784 in 2024, representing 65% of all operating expenses.
Last updated: 2026-07-09